AI Proteins is a Boston-based biotechnology company that designs de novo miniprotein therapeutics using AI-based computational protein design and a high-throughput drug discovery platform. It develops small, modular, multispecific protein constructs intended to be potent, programmable and safe for therapeutic applications, and pursues partnerships with biopharmaceutical companies alongside its internal pipeline. The company was founded in 2021 and is led by CEO Chris Bahl.